- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NATTOPHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 64,60 | +0,53 % | EU Approves DAWNZERA For Hereditary Angioedema, Says Ionis And Otsuka | TOKYO (dpa-AFX) - Ionis Pharmaceuticals, Inc. (IONS) and Otsuka Pharmaceutical Co., Ltd. on Wednesday said the European Commission has approved Dawnzera to prevent repeated attacks of hereditary... ► Artikel lesen | |
| CSPC PHARMA | 0,982 | -4,20 % | CSPC PHARMA (01093): UPDATE ANNOUNCEMENT - CONNECTED TRANSACTION IN RELATION TO THE DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY | ||
| SELLAS LIFE SCIENCES | 4,440 | +6,73 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 19,185 | -0,62 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,900 | +0,92 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 435,00 | -2,18 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| OPUS GENETICS | 4,620 | +5,48 % | Opus Genetics, Inc.: Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital | - Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment -- Strategic financing to accelerate development of earlier-stage... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets | Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 5,050 | 0,00 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,100 | +10,53 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update | NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 3,280 | -2,38 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenCA65564N1006 Westgold Metals Corp. 02.04.2026 CA96033F1053 Westgold Metals Corp. 07.04.2026 Tausch 1:1BMG0403V2062 APAC... ► Artikel lesen | |
| CGN MINING | 0,480 | +1,27 % | CGN MINING (01164): PROPOSED RE-DOMICILIATION INVOLVING AMENDMENT OF CAYMAN ARTICLES, ADOPTION OF CHINESE NAME AND ADOPTION OF HONG KONG ARTICLES | ||
| ARCTICZYMES TECHNOLOGIES | 1,760 | -1,68 % | Brenntag Signs Exclusive Distribution Deal With ArcticZymes | MUEHLHEIM (dpa-AFX) - Brenntag SE (BNTGF.PK), Wednesday announced an exclusive distribution agreement with ArcticZymes AS on the salt-active nucleases - SAN HQ, SAN-HQ GMP, M-SAN HQ, M-SAN HQ... ► Artikel lesen | |
| PHOTOCURE | 5,150 | -2,09 % | Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway | OSLO, Norway, March 16, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology... ► Artikel lesen | |
| CIPHER PHARMACEUTICALS | 11,600 | 0,00 % | Cipher Pharmaceuticals übertrifft Gewinnerwartungen, verfehlt aber Umsatzziel |
Das Unternehmen NATTOPHARMA ASA kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NATTOPHARMA ASA finden Sie auf Wallstreet Online.